At a glance
- Originator BioCryst Pharmaceuticals
- Class Small molecules
- Mechanism of Action Complement C1 inhibitors; Complement factor D inhibitors; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 25 Jan 2005 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 27 Apr 2001 No-Development-Reported for Inflammation in USA (Unknown route)
- 03 Sep 1998 Preclinical development for Inflammation in USA (Unknown route)